Daily or monthly ibandronate prevents or restores deteriorations of bone mass, architecture, biomechanical properties and markers of bone turnover in androgen-deficient aged rats

References

• National Institute of Health. Osteoporosis prevention, diagnosis, and therapy. NIH Consens Statement 2000;17:1–36.
   Google Scholar
• Melton LJ, Atkinson EJ, O'Connor MK, O'Fallon WM, Riggs BL. Bone density and fracture risk in men. J Bone Miner Res 1998;13:1915–1923.
   PubMed Web of Science ®Google Scholar
• Bauss F, Schimmer RC. Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis. Ther Clin Risk Manage 2006;2:3–18.
   PubMedGoogle Scholar
• Kamel HK. Male osteoporosis: new trends in diagnosis and therapy. Drugs Aging 2005;22:741–748.
   PubMed Web of Science ®Google Scholar
• Rackoff P. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Clin Interv Aging 2009;4:207–214.
   Web of Science ®Google Scholar
• Piper PK, Gruntmanis U; Management of osteoporosis in the aging male: focus on zoledronic acid. Clin Interv Aging 2009;4:289–303.
   Web of Science ®Google Scholar
• Ringe JD, Dorst A, Faber H, Ibach K, Sorenson F. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int 2003;14:801–807.
   PubMed Web of Science ®Google Scholar
• Fahrleitner-Pammer A, Piswanger-Soelkner JC, Pieber TR, Obermayer-Pietsch BM, Pilz S, Dimai HP, Prenner G, Tscheliessnigg KH, Hauge E, Portugaller RH, Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial. J Bone Miner Res 2009;24:1335–1344.
   PubMed Web of Science ®Google Scholar
• Stepan JJ, Burckhardt P, Hána V. The effects of three-month intravenous ibandronate on bone mineral density and bone remodeling in Klinefelter's syndrome: the influence of vitamin D deficiency and hormonal status. Bone 2003;33:589–596.
   Google Scholar
• Orwoll ES, Binkley NC, Lewiecki EM, Gruntmanis U, Fries MA, Dasic G. Efficacy and safety of monthly ibandronate in men with low bone density. Bone 2010;46:970–976.
   PubMedGoogle Scholar
• Rockville, MD; Food and Drug Administration. United States Food and Drug Administration Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis; 1994
   Google Scholar
• Committee for Proprietary Medicinal Products (CPMP). Note for guidance on involutional osteoporosis in womenLondon: The European Agency for the Evaluation of Medicinal Products; Human Medicines Evaluation Unit; 2001.
   Google Scholar
• Committee for Medicinal Products for Human use (CHMP). Guideline for the evaluation of medicinal products in the treatment of primary osteoporosisLondon: European Medicines Agency Human Medicines Evaluation Unit; 2006.
   Google Scholar
• Bauss F, Russell RGG. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos Int 2004;15:423–433.
   PubMed Web of Science ®Google Scholar
• Bauss F, Dempster DW. Effects of ibandronate on bone quality: preclinical studies. Bone 2007;40:265–273.
   PubMed Web of Science ®Google Scholar
• Hothorn LA, Bauss F. Biostatistical design and analyses of long-term animal studies simulating human postmenopausal osteoporosis. Drug Inf J 2004;38:47–56.
   Google Scholar
• World Health Organization. Guidelines for preclinical evaluation and clinical trials in osteoporosis. Geneva: WHO; 1998.
   Google Scholar
• Borchers RE, Gibson LJ, Burchardt H, Hayes WC. Effects of selected thermal variables on the biomechanical properties of trabecular bone. Biomaterials 1995;16:545–551.
   PubMed Web of Science ®Google Scholar
• Gala J, Díaz Curiel M, De la Piedra C, Castilla C, Torralbo M. Bone mass assessment in rats by dual energy X-ray absorptiometry. Br J Radiol 1998;71:754–758.
   Google Scholar
• Feldkamp LA, Davis LC, Kress JW. Practical cone-beam algorithm. J Opt Soc Am A 1984;1:612–619.
   Google Scholar
• Hildebrand T, Ruegsegger P. A new method for the model-independent assessment of thickness in three-dimensional images. J Microsc 1997;185:67–75.
   Web of Science ®Google Scholar
• Ulrich D, Van RB, Laib A, Ruegsegger P. The ability of three-dimensional structural indices to reflect mechanical aspects of trabecular bone. Bone 1999;25:55–60.
   PubMed Web of Science ®Google Scholar
• Hildebrand T, Ruegsegger P. Quantification of bone microarchitecture with the Structure Model Index. Comput Methods Biomech Biomed Eng 1997;1:15–23.
   PubMedGoogle Scholar
• Harrigan TP, Mann RW. Characterisation of microstructural anisotropy in orthotropic materials using a second rank tensor. J Mater Sci 1984;19:761–767.
   Web of Science ®Google Scholar
• Hahn M, Vogel M, Pompesius-Kempa M, Delling G. Trabecular bone pattern factor, a new parameter for simple quantification of bone microarchitecture. Bone 1992;13:327–330.
   PubMed Web of Science ®Google Scholar
• Jamsa T, Jalovaara P, Peng Z, Vaananen HK, Tuukkanen J. Comparison of threepoint bending test and peripheral quantitative computed tomography analysis in the evaluation of the strength of mouse femur and tibia. Bone 1998;23:155–161.
   PubMed Web of Science ®Google Scholar
• Saffar KP, JamilPour N, Rajaai SM. How does the bone shaft geometry affect its bending properties? Am J Appl Sci 2009;6:463–470.
   Google Scholar
• Turner CH. Biomechanics of bone: determinants of skeletal fragility and bone quality. Osteoporos Int 2002;13:97–104.
   PubMed Web of Science ®Google Scholar
• Erben RG, Eberle J, Stahr K, Goldberg M. Androgen deficiency induces high turnover osteopenia in aged male rats: a sequential histomorphometric study. J Bone Miner Res 2000;15:1085–1098.
   PubMed Web of Science ®Google Scholar
• Blouin S, Libouban H, Moreau MF, Chappard D. Orchidectomy models of osteoporosis. Methods Mol Biol 2008;455:125–134.
   Google Scholar
• Bauss F, Lalla S, Endele R, Hothorn LA. The effects of treatment with ibandronate on bone mass, architecture, biomechanical properties and bone concentration of ibandronate in ovariectomized aged rats. J Reumathol 2002;29:2200–2208.
   PubMed Web of Science ®Google Scholar
• Libouban H, Moreau MF, Legrand E, Audran M, Baslé MF, Chappard D. Comparison of histomorphometric descriptors of bone architecture with dual-energy X-ray absorptiometry for assessing bone loss in the orchidectomized rat. Osteoporos Int 2002;13:422–428.
   PubMedGoogle Scholar
• Epstein S, Zaidi M; Biological properties and mechanism of action of ibandronate: application to the treatment of osteoporosis. Bone 2005;37:433–440.
   PubMed Web of Science ®Google Scholar
• Bauss F, Wagner M, Hothorn LH. Total administered dose of ibandronate determines its effect on bone mass and architecture in ovariectomized aged rats. J Reumathol 2002;29:990–998.
   PubMed Web of Science ®Google Scholar
• Vanderschueren D, Van Herk D, Sinker AMH, Visser WJ, Shot LPC, Bouillon R. Bone and mineral metabolism in aged male rats: short and long term effects on androgen deficiency. Endocrinology 1992;130:2906–2916.
   PubMed Web of Science ®Google Scholar
• Rissanen JP, Suominen MI, Peng Z, Morko J, Rasi S, Risteli J, Halleen JM. Short-term changes in serum PINP predict long-term changes in trabecular bone in the rat ovariectomy model. Calcif Tissue Int 2008;82:155–161.
   PubMed Web of Science ®Google Scholar
• Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B, Reginster JY, Recker RR, Hughes C, Lewiecki EM, Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 2005;20:1315–1322.
   PubMed Web of Science ®Google Scholar
• Reginster JY, Adami S Lakatos P. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006;65:654–661.
   PubMed Web of Science ®Google Scholar
• Monier-Faugere MC, Geng Z, Paschalis EP, Qi Q, Arnala I, Bauss F, Boskey AL, Malluche HH. Intermittent and continuous administration of the biphosphonate ibandronate in ovariohysterectomized beagle dogs: Effects on bone morphometry and mineral properties. J Bone Miner Res 1999;14:1768–1778.
   PubMed Web of Science ®Google Scholar
• Lamy O, Sandini L, Pache I, Fatio S, Burnand J, Burckhardt P. Intravenous ibandronate in men with osteoporosis: an open pilot study over 2 years. J Endocrinol Invest 2003;26:728–732.
   Google Scholar